The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index; 346 of the 558 sources its claims cite were checked for support.
Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges
Open accessAbstract
Radiotherapy is a cornerstone of breast cancer treatment, but its efficacy is frequently limited by intrinsic and acquired radioresistance as well as dose-limiting toxicity to surrounding normal tissues. Nanoparticle-mediated radiosensitization has emerged as a promising strategy to enhance the therapeutic index of irradiation by combining physical dose amplification with biological, microenvironmental, and immunological modulation. In this systematic review, we evaluated preclinical evidence on nanoparticle-mediated radiosensitization in breast cancer, with emphasis on nanoplatform design, mechanistic patterns, therapeutic efficacy, and translational relevance. A total of 66 studies published between 2015 and 2026 were included. The identified systems encompassed a broad range of materials, including gold-, silver-, platinum-, bismuth-, gadolinium-, polymer-, lipid-, and hybrid-based nanoplatforms, frequently incorporating targeting ligands, catalytic components, biomimetic coatings, or therapeutic payloads. Enhanced radiation responses were most commonly associated with high-atomic-number (high-Z)-mediated energy deposition, increased reactive oxygen species generation, and enhanced DNA damage persistence. Additional mechanisms, including redox modulation, hypoxia targeting, regulated cell death, and immune activation, reflect the evolution of nanoparticle-assisted radiotherapy from predominantly physical radioenhancement toward multifunctional physicobiological strategies. Triple-negative breast cancer models predominated throughout the literature. Across preclinical models, nanoparticle-assisted irradiation consistently improved clonogenic survival, tumor control, and, in selected studies, survival. However, substantial heterogeneity in study design and limited use of rigorous radiobiological endpoints restricted cross-study comparability. The available preclinical evidence indicates that the most promising nanoparticle-mediated radiosensitization strategies integrate physical dose enhancement with biologically active mechanisms targeting oxidative stress, hypoxia, persistent DNA damage, immune signaling, and tumor microenvironmental resistance. Collectively, these findings suggest that the field is evolving from predominantly physical radioenhancement toward multifunctional, mechanism-driven physicobiological strategies. However, clinical translation remains constrained by methodological heterogeneity and limited radiobiological validation, highlighting the need for standardized preclinical evaluation and clinically feasible nanoplatforms tailored to subtype-specific mechanisms of radioresistance.
Overview
CoChat Summary
TL;DR
This systematic review synthesizes 66 preclinical studies (2015–2026) on nanoparticle-mediated radiosensitization in breast cancer, finding that enhanced radiation responses are most often linked to high-Z dose amplification, ROS generation, and DNA damage. Multifunctional nanoplatforms show broader therapeutic effects, but clinical translation is constrained by methodological heterogeneity and limited formal radiobiological validation.
Key findings
- Among 66 included studies, triple-negative breast cancer was the predominant model (39/66, 59%), followed by HER2-positive (4/66, 6%), luminal (1/66, 2%), mixed/multiple subtypes (6/66, 9%), and general/unspecified models (16/66, 24%); 44/66 (67%) combined in vitro and in vivo work, 16/66 (24%) were in vitro only, and 6/66 (9%) were in vivo only.
- Mechanistic endpoints were dominated by ROS generation (63/66, 95.5%) and enhanced DNA damage (50/66, 75.8%); regulated cell death was investigated in 32/66 (48.5%), most commonly apoptosis (23/66, 34.8%), while ferroptosis (5/66, 7.6%), immunogenic cell death (3/66, 4.5%), and pyroptosis (2/66, 3.0%) were less frequent; hypoxia modulation and immune activation were reported in 10/66 (15.2%) and 11/66 (16.7%), respectively.
- Formal radiobiological validation was limited: clonogenic survival assays were reported in 26/66 studies (39% or 39.4%), SER/DEF metrics in only 5/66 (8% or 7.6%), survival outcomes in 5/66 (8%), toxicity/safety assessments in 22/66 (33%), and comprehensive radiotherapy protocol reporting in only 8/66 (12%).
- Representative outcomes included CXCR4-targeted gold nanoparticles with a DEF10 of 1.20, Au–Pt bimetallic nanoparticles reducing 4T1 tumor volume from 459.5 ± 76.09 mm³ after irradiation alone to 231.7 ± 63.35 mm³ with combined treatment, HfO2@MnO2–GOx inhibiting primary tumor growth by approximately 67% and distant tumor growth by up to 98.7%, and Au@AgBiS2-PEG leaving approximately 50% of treated animals alive at 60 days versus complete control mortality within 14–43 days.
Methods
- PRISMA-guided systematic review prospectively registered in PROSPERO (CRD420261365298); MEDLINE/PubMed and EMBASE were searched from 1 January 2015 to 2 March 2026 for English-language preclinical original studies on nanoparticle-based radiosensitization in breast cancer with irradiation.
- From 1,905 records, 393 duplicates were removed, 1,512 records were title/abstract screened, 199 full texts were assessed, and 66 studies met inclusion criteria; data were extracted using a predefined framework, and study quality was assessed across six domains.
- Because of heterogeneity in nanoplatforms, models, irradiation protocols, and outcomes, no formal meta-analysis was performed; data were synthesized qualitatively, with radiosensitization distinguished from radioenhancement based on validated endpoints such as clonogenic survival, SER, DEF, or DMF.
Limitations
- The paper states substantial heterogeneity in nanoparticle composition, functionalization, experimental models, radiotherapy protocols, and outcome assessment; radiotherapy reporting was frequently incomplete, especially dose rate, fractionation, beam energy, and treatment timing, and only 8/66 studies (12%) provided comprehensive radiation details.
- The paper states that mechanistic interpretation was often based on associative biomarkers rather than pathway-specific inhibition or rescue experiments, and that formal radiosensitization was inconsistently demonstrated because clonogenic assays and SER/DEF metrics were used in only 26/66 (39%) and 5/66 (8%) studies, respectively.
- The paper also states that TNBC models predominated while HER2-positive and luminal subtypes were underrepresented, that complex integrated nanoplatforms raise concerns about reproducibility, scalability, biodistribution, long-term toxicity, immunogenicity, and regulatory approval, and that publication bias toward positive findings may overestimate benefit; evident from the text, the qualitative design and lack of meta-analysis preclude quantitative cross-platform comparison.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Quantitative overview of the included studies and radiobiological validation endpoints. (A) Distribution of breast cancer molecular subtypes represented in the 66 included studies. (B) Distribution of experimental designs according to the use of in vitro, in vivo, or combined in vitro/in vivo models. (C) Frequency of key radiobiological validation endpoints, including clonogenic survival assays, formal radiosensitization metrics (sensitizer enhancement ratio [SER] or dose enhancement factor [DEF]), and survival assessment. The figure highlights the predominance of triple-negative breast cancer (TNBC) models, the widespread use of combined experimental designs, and the limited use of gold-standard radiobiological validation endpoints across the included literature.](https://figures.cochat.ai/paper-figures/e6bd2dc443b342c8a1b2ee3dc2c898bd/nanoparticle-mediated-radiosensitization-in-breast-cancer-a-systematic-review-of-figure-2.jpg)

Verification
Claims the paper makes
107 Valid · 7 Not valid · 14 Not checked · 130 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Some studies also reported systemic effects, including responses in non-irradiated tumor sites [17,22,36].”
§ Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges > 3. Results > 3.5. Radiosensitization Mechanisms
What the sources say
- Supportedcites [17] Hu, 2024, Radiotherapy-sensitized cancer immunotherapy via cGAS-STING immune pathway by activatable nanocascade reaction, J. Nanobiotechnol. source
The Results and discussion section (“Immune response activation in vivo”; page not provided) reports inhibition of contralateral distant tumors in mice and attributes their regression to a systemic anti-tumor immune response. The Methods describe irradiation applied locally to the tumor region, supporting the description of the distant tumors as non-irradiated sites. (LLM, conf=0.93)
- Supportedcites [22] Chen, 2025, Bacterial membrane-modified cerium oxide nanoboosters enhance systemic antitumor effects of radiotherapy in metastatic triple-negative breast cancer, J. Nanobiotechnol. source
The Results section, “Nanoboosters suppress pre-existing distant tumor proliferation” (page unavailable), reports regression of distant untreated tumors after treatment of the primary tumors with nanoboosters and X-ray irradiation. This supports the claim of a response at non-irradiated tumor sites; the finding was in a mouse model. (LLM, conf=0.93)
- Disputedcites [36] Yu, 2023, Gadolinium Oxide Nanoparticles Reinforce the Fractionated Radiotherapy-Induced Immune Response in Tri-Negative Breast Cancer via cGAS-STING Pathway, Int. J. Nanomed. sourceExperimental — accuracy not yet measured
The Results section on in vivo radiosensitization reports improved control of the locally irradiated tumor, but says the treatment did not improve inhibition of lung metastases. Thus, this paper does not report the claimed response at a non-irradiated tumor site; its reported distant-site result points the other way. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Mechanistic conclusions also varied in strength, as increased ROS generation, γ-H2AX expression, or hypoxia-related changes were frequently interpreted as evidence of causal pathway involvement without inhibitor-based or rescue experiments confirming mechanistic specificity [17,21,31,39,45,77].”
§ Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges > 4. Discussion > 4.7. Methodological Limitations of Preclinical Evidence
What the sources say
- Partly supportedcites [17] Hu, 2024, Radiotherapy-sensitized cancer immunotherapy via cGAS-STING immune pathway by activatable nanocascade reaction, J. Nanobiotechnol. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [21] Wang, 2024, Oxygen self-supplying nanoradiosensitizer activates cGAS-STING pathway to enhance radioimmunotherapy of triple negative breast cancer, J. Control. Release source
- Supportedcites [31] Montazersaheb, 2026, Radiosensitizing effects of silver nanoparticles targeting angiogenesis and matrix metalloproteinase signaling in triple negative breast cancer cell lines, Sci. Rep. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Supportedcites [39] Xiao, 2023, Multifunctional Au@AgBiS2 Nanoparticles as High-Efficiency Radiosensitizers to Induce Pyroptosis for Cancer Radioimmunotherapy, Adv. Sci. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [45] Yang, 2026, A TNBC-targeting nano-radiosensitizer reverses radioresistance by synergizing GSH scavenging with dual inhibition of Trop2 and lncRNA MNX1-AS1, Biomaterials source
- Disputedcites [77] Aishajiang, 2025, Concurrent Amplification of Ferroptosis and Immune System Activation Via Nanomedicine-Mediated Radiosensitization for Triple-Negative Breast Cancer Therapy, Adv. Sci. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 2 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Biomimetic strategies, including cell membrane-coated nanoparticles, were reported to enhance circulation time and immune evasion [34,44,50,56].”
§ Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges > 3. Results > 3.3. Characteristics of Nanoplatforms, Experimental Models, and Radiotherapy Protocols
What the sources say
- Not checked — no full text of the sourcecites [34] Deng, 2018, Tumor targeted, stealthy and degradable bismuth nanoparticles for enhanced X-ray radiation therapy of breast cancer, Biomaterials source
- Supportedcites [44] Chen, 2024, Nanofabrications of Erythrocyte Membrane-Coated Telmisartan Delivery System Effective for Radiosensitivity of Tumor Cells in Mice Model, Int. J. Nanomed. source
The Introduction states that biomimetic erythrocyte-membrane coating can help a drug-delivery system escape macrophage recognition and clearance, and that ECM-coated systems have long circulation in vivo. These statements support the attributed claim about immune evasion and circulation time. (LLM, conf=0.93)
- Partly supportedcites [50] Zhang, 2026, Novel Pt@BSA nanoparticles improve radiotherapeutic outcomes in breast cancer, RSC Med. Chem. sourceExperimental — accuracy not yet measured
The Abstract identifies Pt@BSA-RM as a biomimetic, red blood cell membrane-coated nanoparticle. The Introduction (page unavailable) attributes a long circulation half-life to its BSA shell, not to the membrane coating; our copy does not report immune evasion by the nanoparticles. Thus the paper supports the example and part of the circulation claim, but not the claimed immune-evasion benefit. (LLM, conf=0.84)
- Partly supportedcites [56] Wang, 2024, Cancer cell membrane-coated siRNA-Decorated Au/MnO2 nanosensitizers for synergistically enhanced radio-immunotherapy of breast cancer, Mater. Today Bio sourceExperimental — accuracy not yet measured
The Results and discussion section (‘In vivo homologous targeting and anti-tumor efficiency’; page unavailable) reports a 3.79-hour blood half-life for the cell membrane-coated nanosensitizer and calls its circulation characteristics favorable. It does not show that membrane coating increased circulation time relative to an uncoated comparator or that the nanoparticles evaded immune clearance. Its discussion of immune evasion concerns tumor-cell PD-L1, not nanoparticle immune evasion. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Receptor-specific targeting approaches, including HER2-, CXCR4-, and folate-directed systems, were described in association with increased cellular uptake [20,24,29,51,54,55].”
§ Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges > 3. Results > 3.3. Characteristics of Nanoplatforms, Experimental Models, and Radiotherapy Protocols
What the sources say
- Supportedcites [20] Bhattarai, 2021, CXC chemokine receptor 4 (CXCR4) targeted gold nanoparticles potently enhance radiotherapy outcomes in breast cancer, Nanoscale source
The Results section (‘Uptake of cGNPs by MDA-MB-231 breast cancer cells’) reports greater cellular uptake of CXCR4-targeted gold nanoparticles than of untargeted particles. The Discussion likewise associates CXCR4 targeting with increased uptake and internalization. This source supports the CXCR4 example in the multiply cited sentence; the HER2 and folate examples are not attributed specifically to it. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [24] Samani, 2020, Trastuzumab and folic acid functionalized gold nanoclusters as a dual-targeted radiosensitizer for megavoltage radiation therapy of human breast cancer, Eur. J. Pharm. Sci. source
- Supportedcites [29] Ghorbani, 2023, Synthesis and characterization of actively HER-2 Targeted Fe3O4@Au nanoparticles for molecular radiosensitization of breast cancer, Bioimpacts source
The Cellular uptake results report greater uptake of trastuzumab-coated nanoparticles than untargeted particles, and the Discussion attributes this to HER-2 overexpression. This supports the HER2-directed example for which this paper is cited in the multi-citation sentence. (LLM, conf=0.92)
- Supportedcites [51] Yamaguchi, H., Hayama, K., Sasagawa, I., Okada, Y., Kawase, T., Tsubokawa, N., and Tsuchimochi, M. (2018). HER2-targeted multifunctional silica nanoparticles specifically enhance the radiosensitivity of HER2-overexpressing breast cancer cells. Int. J. Mol. Sci., 19. source
The Results (§2.1; page unavailable) report that anti-HER2 PCSN probes were internalized by HER2-overexpressing SK-BR3 cells and describe stronger cell-surface fluorescence than in a HER2-negative control. This supports the HER2-targeting and cellular-uptake portion attributable to this paper; the other citations in the sentence address the other receptor-directed systems. (LLM, conf=0.88)
- Partly supportedcites [54] Nosrati, 2022, Magnetite and bismuth sulfide Janus heterostructures as radiosensitizers for in vivo enhanced radiotherapy in breast cancer, Biomater. Adv. sourceExperimental — accuracy not yet measured
Section 3.3.4 (page unavailable) reports that folic-acid conjugation enhanced nanoparticle internalization compared with non-targeted particles. The cited paper supports the folate-directed part of the sentence, but the passages do not describe HER2- or CXCR4-directed uptake. (LLM, conf=0.88)
- Partly supportedcites [55] Ghaffarlou, 2023, Facile preparation of silver based radiosensitizers via biomineralization method for enhanced in vivo breast cancer radiotherapy, Sci. Rep. sourceExperimental — accuracy not yet measured
The Results section (‘Cellular uptake and internalization efficacy’; page not provided) reports greater uptake of folic-acid-conjugated nanoparticles than unconjugated nanoparticles by 4T1 breast cancer cells and links this to folate receptors. The cited paper does not describe HER2- or CXCR4-directed uptake, so it supports only the folate-directed part of the sentence. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Increased ROS production and DNA damage following irradiation were commonly reported in association with these systems [15,20,27,30,33], as summarized in Table 2.”
§ Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges > 3. Results > 3.4. Nanoplatform Design and Functionalization Strategies
What the sources say
- Supportedcites [15] Sun, 2022, AGuIX nanoparticles enhance ionizing radiation-induced ferroptosis on tumor cells by targeting the NRF2-GPX4 signaling pathway, J. Nanobiotechnol. source
The Results section reports that irradiated breast cancer cells treated with AGuIX nanoparticles produced more ROS and showed more DNA fragmentation and γH2AX foci than cells receiving irradiation alone. This paper supports the cited sentence as one reported example; page numbers are not available in the supplied copy. (LLM, conf=0.92)
- Supportedcites [20] Bhattarai, 2021, CXC chemokine receptor 4 (CXCR4) targeted gold nanoparticles potently enhance radiotherapy outcomes in breast cancer, Nanoscale source
The Results sections on reactive oxygen species and DNA double-strand breaks report that CXCR4-targeted gold nanoparticles increased both outcomes after irradiation of MDA-MB-231 breast cancer cells, compared with radiation alone. This paper supports the cited sentence as an example of those effects in a high-Z gold nanoparticle system. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [27] Cui, 2017, Significant Radiation Enhancement Effects by Gold Nanoparticles in Combination with Cisplatin in Triple Negative Breast Cancer Cells and Tumor Xenografts, Radiat. Res. source
- Partly supportedcites [30] Swanner, 2015, Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells, Int. J. Nanomed. sourceExperimental — accuracy not yet measured
The Results section reports increased DNA-damage marker γH2AX after irradiation in silver-nanoparticle-treated breast cells compared with radiation alone. The Discussion says silver nanoparticles increase intracellular ROS, but does not establish increased ROS production following irradiation; it describes ROS findings from nanoparticle exposure without that condition. No page numbers are available in our copy. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [33] Rashidzadeh, 2023, Preparation of alginate coated Pt nanoparticle for radiosensitization of breast cancer tumor, Int. J. Biol. Macromol. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
177 more claims · 67 with their cited sources checked
Create a free account to see all 258 claims and every source verdict.
- It may state two separate claims as one. 69
- Probably not a substantial claim. 11
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges > 4. Discussion > 4.8. Barriers to Clinical Translation
“Although NBTXR3 is currently being evaluated in a phase I dose-escalation/dose-expansion study that includes metastatic triple-negative breast cancer among the expansion cohorts, dedicated breast cancer clinical data remain limited [118,119].”
§ Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges > References
“118. A Phase II Study of High Dose Radiotherapy in Combination with Pembrolizumab Plus Chemotherapy in Patients with PD-L1 Positive Metastatic Triple Negative Breast Cancer (NCT06492759) ClinicalTrials.gov Available online: https://clinicaltrials.gov (accessed on 25 June 2026)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges > 4. Discussion > 4.2. Functional Categories of Nanoparticle-Mediated Radiosensitization
“The most advanced category comprises multifunctional nanoplatforms integrating multiple complementary radiosensitization strategies within a single system [17,21,23,26,39,40,45,52,53].”
§ Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges > 3. Results > 3.3. Characteristics of Nanoplatforms, Experimental Models, and Radiotherapy Protocols
“[15,16,17,19,20,21,22,24,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84]”
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873 · cited 5×
“…local radiation absorption, secondary electron generation, and ROS production, they do not directly address major biological determinants of radioresistance, including tumor hypoxia, antioxidant defenses, DNA repair capacity, immune suppression, and heterogeneous nanoparticle delivery [4,12,85,93].”
InfluentialMaeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376 · cited 3×
“Nanoparticles can be engineered with precise control over size, shape, composition, and surface functionalization, enabling tailored interactions with biological systems and selective accumulation in tumor tissues [11,12].”
Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements
Her, S., Jaffray, D. A., & Allen, C. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.012 · Cited by 865 · cited 3×
“…radiosensitization is the use of high-atomic-number (high-Z) materials, such as gold, hafnium, bismuth, and gadolinium, which exhibit increased photoelectric absorption and generate secondary electrons under irradiation, thereby amplifying local radiation dose deposition [9,13].”
Opportunities and challenges of radiotherapy for treating cancer
Schaue, D., & McBride, W. H. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.120 · Cited by 784 · cited 2×
“Hypoxia is one of the most important determinants of radiotherapy response because reduced oxygen availability limits stabilization of radiation-induced DNA damage and decreases sensitivity to ionizing radiation [6].”
Pathogenesis of Triple-Negative Breast Cancer
Derakhshan, F., & Reis-Filho, J. S. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042420-093238 · Cited by 714 · cited 4×
“These challenges are particularly pronounced in aggressive subtypes such as triple-negative breast cancer (TNBC), which is characterized by high genomic instability, lack of actionable receptors, and poor clinical outcomes [8].”
InfluentialGold Nanoparticles as Radiosensitizers in Cancer Radiotherapy
Chen, Y., Yang, J., Fu, S., & Wu, J. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s272902 · Cited by 319 · cited 9×
“Nanotechnology has emerged as a promising strategy for enhancing radiation response because nanoparticles can be engineered to promote both physical dose amplification and biological modulation, thereby increasing the potential for radiosensitization [9,10].”
InfluentialBonvalot, S., Le Pechoux, C., De Baere, T., Kantor, G., Buy, X., Stoeckle, E., Terrier, P., Sargos, P., Coindre, J. M., Lassau, N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1297 · Cited by 243 · cited 2×
“Hafnium oxide nanoparticles (NBTXR3/Hensify) represent the most advanced example, demonstrating clinical efficacy in combination with radiotherapy and obtaining regulatory approval for locally advanced soft tissue sarcoma, with ongoing evaluation in additional tumor types [112–115].”
Deng, J., Xu, S., Hu, W., Xun, X., Zheng, L., & Su, M. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.048 · Cited by 234 · cited 8×
“[15,20,27,28,30,33,34,36,50,63].”
Influential
Research works printed but not linked: 1
- Bray, 2024, Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide, CA Cancer J. Clin., 74, 229
Metadata
- Authors
- Lunca, S., Morarasu, S., & Dimofte, G. M.
- Affiliations
- Grigore T Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
- Grigore T. Popa University of Medicine and Pharmacy (RO)
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2026-07-22
- Volume
- 27
- Issue
- 14
- Pages
- 6522
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC13411440
- OpenAlex
- W7170042542
- Cited by
- 2
- References
- 114
- Citations by year
- 2026: 2
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- Grigore T. Popa University of Medicine and Pharmacy (326475)
- Topics
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Physics and Astronomy › Radiation › Advanced Radiotherapy Techniques
- Keywords
- breast cancer, radioresistance (biology), gold nanoparticles, platinum nanoparticles, bismuth nanoparticles, gadolinium nanoparticles, reactive oxygen species, redox modulation, tumor microenvironment, triple-negative breast cancer, immune activation, translational challenges
- MeSH terms
- Animals, Breast Neoplasms, Female, Humans, Radiation Tolerance, Radiation-Sensitizing Agents, Nanoparticles, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges. https://app.cochat.ai/papers/10.3390/ijms27146522
- The paper
- Lunca, S., Morarasu, S., & Dimofte, G. M. (2026). Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27146522
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.